References
- [No authors listed]2007ISA 247: trans-ISA 247, trans-R 1524, ISA(TX)247, ISAtx 247, ISATx247, LX 211, LX211, R 1524, R-1524Drugs R D81031217324008
- AbelMDAspesletLJFosterRT2003ISA247 A new generation calcineurin inhibitor [abstract]Proceedings of the International Association of Therapeutic Drug MonitoringBaselSwitzerland
- AbelMMullerFFreitagD20043D structure of ISA247 correlates with improved cyclophilin binding and calcineurin inhibition [abstract]Proceedings of the 3rd International Congress on ImmunosuppressionSan Diego, CA, USA150489
- AspesletLFreitagDTrepanierD2001ISA(TX)247: a novel calcineurin inhibitorTransplant Proc3310485111267185
- AspesletLFreitagDHuizingaRB2004Pharmacokinetics-pharmacodynamics and safety of Trans-ISA247: A novel immunosuppressant [abstract]Proceedings of the 3rd International Congress on ImmunosuppressionSan Diego, CA, USA150367
- BusqueSLaftaviMGastonR2007ISA247: Preliminary results of a phase IIb multicentre, de novo renal transplant trial [abstract]Proceedings of the American Transplant Congress May 6, 200749
- ChoMlChoCSMinSY2002Cyclosporine inhibition of vascular endothelial growth factor production in rheumatoid synovial fibroblastsArthritis Rheum461202912115224
- CunninghamMALiZChanCC2007Subcutaneous injections of LX211 prevent and reverse experimental autoimmune uveoretinitis in rats [poster]Proceedings of the Association for Research in Vision and Ophthalmology Annual MeetingMay 6th–10thFort Lauderdale, FL, USAB730
- DumontFJLiebermanRMukherjeeA1996Cyclosporine A and tacrolimus (FK-506) immunosuppression through immunophilin-dependent inhibition of calcineurin functionPrinciples of Drug Development in Transplantation and AutoimmunityNew YorkChapman and Hall1175205
- DumontFJ2004ISAtx-247 (Isotechnika/Roche)Curr Opin Investig Drugs554250
- FreitagDMayoPAspesletL2006The novel immunosuppressant ISA247 demonstrates a different metabolic profile than cyclosporine A in vitro and in vivo [abstract]Proceedings of the World Transplant CongressJuly 22nd–27thBoston, MA, USA2434
- GastonRBusqueSCantarovichMfor the PROMISE Study Investigators2006ISA247: A novel calcineurin inhibitor (CNI). A promising safety profile with enhanced efficacy [poster]Proceedings of the American Society of Nephrology,San Diego, CA, USA
- GritzDCWongIG2004Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis StudyOphthalmology11149150015019324
- GuentherLBarberKVenderR2006ISA247 Remains a safe and efficacious agent after 48 weeks of continuous therapy: interim results of the SPIRIT Extension Study [abstract]Proceedings of the American 15th Congress of the European Academy of Dermatology and VenereologyOctober 4th–8thRhodes, Greece950670
- GuptaATomiZKunynetzR2006Pharmacokinetics and pharmacodynamics of ISA247 in a Phase III, randomized, multicentre, double-blind, placebo-controlled study [abstract]Canadian Dermatology Association 81st Annual ConferenceJune 27th–July 2ndWinnipeg, Canada
- HoSClipstoneNTimmermannL1996The mechanism of action of cyclosporin A and FK506Clin Immunol Immunopathol803 Pt 2S40S458811062
- Isotechnika, Inc.2008Data on fileIsotechnika, Inc.Edmonton, Canada
- Isotechnika, Inc.2007aPhase I study summariesAccessed July 8, 2007 URL: http://www.isotechnika.com/in_development/isa247/how/
- Isotechnika, Inc.2007bPhase 3 Canadian Psoriasis StudyAccessed July 8, 2007 URL: http://www.isotechnika.com/in_development/isa247/psoriasis
- JabsAKaramurselE2005Immunosuppression for posterior uveitisRetina2511815655435
- JabsDANussenblattRBRosenbaumJT2005Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International WorkshopAm J Ophthalmol1405091616196117
- JabsDARosenbaumJTFosterCS2000Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: Recommendations of an expert panelAm J Ophthalmol13049251311024423
- LangleyRBissonnetteRSearlesG200624 Week results of a Phase III randomized, double-blind, multicentre, placebo-controlled study of ISA247 in plaque psoriasis [abstract]Canadian Dermatology Association 81st Annual ConferenceJune 27th–July 2ndWinnipeg, Canada
- NussenblattRB1990The natural history of uveitisInt Ophthalmol1430382249907
- PappKLangleyRBissonnetteR2004A Phase III, randomized, multicenter, double-blind, placebo-controlled study of ISA247 in plaque psoriasis patients [abstract]J Am Acad Dermatol54Suppl 1P33
- SchreiberSLCrabtreeGR1992The mechanism of action of cyclosporin A and FK-506Gr Immunol Today1313642
- StaatzCETettSE2004Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantationClin Pharmacokinet436235315244495
- StalderMBirsanTHubbleRW2003In vivo evaluation of the novel calcineurin inhibitor ISATX247 in non-human primatesJ Heart Lung Transplant2213435214672749
- VollenbroekerBKochJHFobkerM2005Determination of cyclosporine and its metabolites in blood via HPLC-MS and correlation to clinically important parametersTransplant Proc371741415919451
- WaselNGuptaATomiZ2006Pharmacokinetics and pharmacodynamics of ISA247 in a Phase III randomized, multicenter, double-blind, placebo-controlled study [abstract]J Am Acad Dermatol54Suppl 1P36
- YatscoffRWBroskiAPAbelMD2002Phase 2 trial results of ISATX247, a novel calcineurin inhibitor with a therapeutic window [abstract]Proceedings of the IXI International Congress of The Transplantation SocietyMiami, FL, USA0471
- YatscoffRWAbelMDAspesletLJ2003Phase 2 randomized, multicenter, open-label study of ISA247 and Neoral in post-renal transplant patients [abstract]Proceedings of the American Transplant CongressWashington DC, USA1215